Prescribing information: difference between revisions
Diff·revision 3 → 4·11:26, 4 Oct 2024
Difference between revision 3 and revision 4 of Prescribing information. 2 lines changed; the page grew by 272 bytes.
| Revision 3 — 01:32, 24 Sep 2024 Peptide_Pete (talk) add the year each price figure refers to 1,931 bytes ±0 | Revision 4 — 11:26, 4 Oct 2024 Peptide_Pete (talk) attribute the survey figure to the survey and give its sample size 2,203 bytes +272 | ||
|---|---|---|---|
| 15 | The clinical studies section reports the trials supporting the indication, with the effect sizes as the regulator accepted them. It is a useful primary-adjacent source: the numbers are those the regulator reviewed rather than those a press release selected.{{r|ema_smpc}} | 15 | The clinical studies section reports the trials supporting the indication, with the effect sizes as the regulator accepted them. It is a useful primary-adjacent source: the numbers are those the regulator reviewed rather than those a press release selected.{{r|ema_smpc}} |
| 16 | 16 | ||
| + | 17 | Warnings and precautions differ from contraindications: a contraindication says the product is not to be used, a warning that a risk exists and is to be managed. Conflating them overstates the restriction. See [[Contraindications of incretin therapy]].{{r|fda_labeling}} | |
| + | 18 | ||
| 17 | == References == | 19 | == References == |
| 18 | {{reflist}} | 20 | {{reflist}} |